1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.3816/cbc.2003.s.010" target="_blank" rel="noreferrer noopener">http://doi.org/10.3816/cbc.2003.s.010</a>
Pages
S10–19
Volume
4 Suppl 1
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Neoadjuvant chemotherapy for operable breast cancer: is this the future?
Publisher
An entity responsible for making the resource available
Clinical breast cancer
Date
A point or period of time associated with an event in the lifecycle of the resource
2003
2003-04
Subject
The topic of the resource
Female; Humans; Time Factors; Randomized Controlled Trials as Topic; Biopsy; Polymerase Chain Reaction; Evidence-Based Medicine; Europe; Breast Neoplasms/*drug therapy/*surgery; *Antineoplastic Combined Chemotherapy Protocols; Neoadjuvant Therapy/*methods/*standards; Neoplasm Staging/methods; Sentinel Lymph Node Biopsy/methods; Clinical Trials; Chemotherapy; Biological Markers; Breast Neoplasms – Drug Therapy; Breast Neoplasms – Surgery; Adjuvant – Methods; Breast Neoplasms – Radiotherapy
Creator
An entity primarily responsible for making the resource
Mamounas Eleftherios P
Description
An account of the resource
The idea of using preoperative or neoadjuvant chemotherapy in patients with operable breast cancer originated from experimental and clinical observations as well as theoretical hypotheses on tumor cell growth and dissemination. Initially, nonrandomized studies demonstrated considerable rates of clinical tumor response, low rates of pathologic complete response (pCR), and increased rates of breast-conserving procedures. However, nonrandomized studies could not address the relative efficacy of neoadjuvant versus adjuvant chemotherapy on disease-free and overall survival. Similarly, earlier randomized trials were not designed as straightforward comparisons of neoadjuvant versus adjuvant chemotherapy and therefore could not adequately address the relative efficacy of neoadjuvant versus adjuvant chemotherapy on outcome. These answers were eventually provided by larger randomized trials that directly compared neoadjuvant with adjuvant chemotherapy, which are reviewed in more detail in this article. Potential advantages and disadvantages of the neoadjuvant approach and surgical considerations in the breast and axilla after neoadjuvant chemotherapy are also discussed. Finally, several recently reported trials of neoadjuvant therapy incorporating newer agents such as taxanes in sequence with anthracycline-containing regimens have shown further increases in pCR rates. Although outcome data are not available yet from these studies, it is hoped that the observed increase in pCR rates will be associated with improved outcome. If the previously observed significant correlation between the achievement of pCR and improved outcome continues to be demonstrated with these newer regimens, it will substantially strengthen the rationale for using neoadjuvant rather that adjuvant chemotherapy in the clinical setting as well as in future research studies.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.3816/cbc.2003.s.010" target="_blank" rel="noreferrer noopener">10.3816/cbc.2003.s.010</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Antineoplastic Combined Chemotherapy Protocols
2003
Adjuvant – Methods
Biological Markers
Biopsy
Breast Neoplasms – Drug Therapy
Breast Neoplasms – Radiotherapy
Breast Neoplasms – Surgery
Breast Neoplasms/*drug therapy/*surgery
Chemotherapy
Clinical breast cancer
Clinical Trials
Europe
Evidence-Based Medicine
Female
Humans
Mamounas Eleftherios P
Neoadjuvant Therapy/*methods/*standards
Neoplasm Staging/methods
Polymerase Chain Reaction
Randomized Controlled Trials as Topic
Sentinel Lymph Node Biopsy/methods
Time Factors